PDCD1 and renal cell carcinoma: Additionally, anti-PD-1 molecules for the management of malignancies such as non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), Hodgkin lymphoma, melanoma, urothelial carcinoma, metastatic colorectal cancer and hepatocellular carcinoma are Food and Drugs Administration (FDA)-consented to be prescribed [28], as summarised in Table 1.